Clinical Trial Update: Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating rotigotine versus placebo for nocturnal hypokinesia in Parkinson's disease, assessed with wearable sensors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Rotigotine (Neupro) (rotigotine)

Snippet

Sponsor: Chulalongkorn University | Conditions: Nocturnal Hypokinesia | Phase 4 | Status: UNKNOWN